Marathon Digital Holdings Inc vs Tango Therapeutics Inc. — how do they compare? Marathon Digital Holdings Inc trades at $8.1 (market cap $3.52B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Marathon Digital Holdings Inc and Tango Therapeutics Inc. are close in size by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Digital Holdings Inc for 22 Days and Tango Therapeutics Inc. for 0 Days on average.
| MARA | TNGX | |
|---|---|---|
Market Cap | $3.52B | $3.75B |
Volume | 36,018,511 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $22.84 | $32.90 |
52-Week Low | $6.73 | $7.50 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $5.56B | $2.77B |
Signals from Pluang's Aura AI — not financial advice
Marathon Digital Holdings (MARA) trades at $9.11, down 3.5% on the day, reflecting ongoing volatility amid mixed technical signals. The stock shows bearish momentum in moving averages but bullish oscillators, with key resistance at $10. Fundamentally, the company reported significant losses with a net income margin of -429.71% in 2026, though valuation ratios appear attractive with P/E of 3.37. Recent news highlights continued analyst coverage and Bitcoin-related sector movements influencing stock performance.
MARA presents a high-risk opportunity with analyst consensus price target of $13 offering 43% upside potential, balanced by 45% buy and 45% hold ratings. However, persistent negative earnings, cash flow challenges, and Bitcoin market dependency create substantial risk. Investors must weigh the discounted valuation against the company's inability to achieve profitability despite revenue generation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →